Access to capital remains the number one priority for emerging biotechnology firms. BIOTECanada works to increase access to financing by encouraging regulatory and legislative changes that create incentives for investors to put their money into this innovative sector.

Financing Facts

  • It takes 10-15 years, and approximately 1.5 billion dollars to commercialize a biotechnology product.
  • 80% of Canadian biotechnology companies are privately owned.
  • The majority of the sector is made up of SMEs:  50% of biotechnology companies have less than 20 employees, and 80 per cent have less than 100 employees.
  • The biotechnology sector is typically more sensitive to market movements than other sectors.
  • The top 25 publicly-traded biotechs in Canada have outpaced the TSX/S&P index since the global economic downturn begun.

Click here to learn more about RBC Financial Services for Life Sciences & Health Services Companies.

MaRS Funding Portal

Use this tool to access more than 4,500 federal, provincial and municipal government funding programs for businesses, non-profits, charities and research institutions. Information on all funds is updated 24/7/365. After entering your search criteria, you will be redirected to The Funding Portal’s website to view your results and further refine your search.

NOTE: This tool redirects you to a third-party website not owned or operated by MaRS and/or BIOTECanada; therefore, MaRS and/or BIOTECanada is not responsible for the content on these linked pages. MaRS and/or BIOTECanada makes no representation or warranty regarding the information appearing on any linked websites.

Partnership Program



Biogen Idec